Juergen Froehlich

Juergen Froehlich’s career in biotechnology spans three decades and covers a broad range of drug development projects and approvals across therapeutic areas such as cerebrovascular, cardiovascular, pulmonary, metabolic, oncologic, genetic, and infectious disorders. He has worked with biologics, peptides, small molecules, and RNA therapeutics at companies including Boehringer Ingelheim, Genentech, Quintiles, Bristol-Myers-Squibb, Ipsen, Vertex, Aradigm, and Genevant. Since 2005, he has mainly been involved with rare diseases including bronchiectasis, cystic fibrosis, non-tuberculous mycobacteria infection, acromegaly, neuroendocrine tumors, urea cycle disorders cervical dystonia, and hemophilia. Juergen was instrumental in obtaining successful marketing authorizations in the US, EMA, and other countries for ODD-designated products in cystic fibrosis, acromegaly, and cervical dystonia. As Chief Medical Officer and Head of Regulatory Affairs of Aradigm Corporation, he implemented a Phase 3 trial program with inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa lung infection and was an invited panel member at a U.S. Food and Drug Administration (FDA) workshop in 2018 for inhaled antibiotics in cystic fibrosis and bronchiectasis. Juergen Froehlich is also serving as a Board member of Appili Therapeutics, a publicly traded infectious disease company in Canada. He received his MD from the Medical School at Wuerzburg University, Germany, is a Diplomate of the American Board of Clinical Pharmacology, and holds an executive MBA degree from the Graduate School of Business Administration in Zurich, Switzerland.